A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

Area of Science:

• Nephrology
• Diabetology
• Molecular Biology

Background:

• Plasminogen activator inhibitor-1 (PAI-1) is linked to renal fibrosis by inhibiting mesangial extracellular matrix turnover.
• A PAI-1 mutant (PAI-1R) enhances plasmin generation and matrix degradation, showing therapeutic potential in experimental glomerulonephritis.

Purpose of the Study:

• To investigate if PAI-1R administration can impede glomerulosclerosis progression in db/db mice, a model for type 2 diabetes.
• To assess PAI-1R's impact on mesangial matrix expansion and associated fibrotic markers in diabetic kidney disease.

Main Methods:

• db/db mice, a model of type 2 diabetes, underwent uninephrectomy.
• Short-term administration of PAI-1R was given to assess its effects on disease progression between 20 and 22 weeks of age.
• Renal mRNA levels of collagen types I and IV, and fibronectin were quantified.

Main Results:

• Untreated mice showed progressive albuminuria and mesangial matrix expansion.
• PAI-1R treatment prevented albuminuria and mesangial matrix expansion.
• PAI-1R administration did not affect body weight, blood glucose, HbA1c, creatinine, or creatinine clearance.

Conclusions:

• PAI-1R effectively prevented the progression of glomerulosclerosis in db/db mice.
• The therapeutic effect of PAI-1R occurred independently of changes in systemic metabolic parameters.
• PAI-1R shows promise as a treatment to slow diabetic kidney disease progression.